Insys Therapeutics reports dismissal of stockholder class action lawsuit Insys Therapeutics announced that the previously reported stockholder class action lawsuit that had been filed against the company and certain of its officers and directors in U.S. District Court for the District of Arizona was on February 20, voluntarily dismissed by the plaintiff and thereafter terminated by the court. No payment or consideration of any kind was made by any of the defendants in connection with the dismissal.
Insys Therapeutics longer term outlook stable, says RBC Capital After surveying 40 doctors, including nine who prescribed large amounts of Insys' Subsys, RBC Capital says that payor pushback on the drug is "limited," while 95% of all the doctors surveyed and 89% of the high prescribers "intend to write as many or more Subsys prescriptions this year" as last year. The firm thinks the stock's valuation is attractive following its 61% pullback since July. It trimmed its price target on the stock to $44 from $49 but keeps an Outperform rating. .